Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.

ABSTRACT:

Background

Diverticular disease treatment is limited to fibres, antibiotics, and surgery. There is conflicting evidence on mesalazine benefits and harms.

Aim

We systematically reviewed current evidence on benefits and harms of mesalazine versus all other treatments in people with diverticular disease.

Methods

We searched MEDLINE, EMBASE, CENTRAL, ClinicalTrials.gov for studies published to July 2018. We estimated risk ratios (RR) for dichotomous outcomes (disease remission/recurrence, acute diverticulitis in symptomatic uncomplicated diverticular disease, need for surgery/hospitalization, all-cause/disease-related mortality, adverse events), mean differences (MD) or standardized MD (SMD) for continuous outcomes (quality of life, symptoms score, time to recurrence/remi

SUBMITTER: Iannone A 

PROVIDER: S-EPMC6167594 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature